Biogen
BIIB
738 hedge funds and large institutions have $60.8B invested in Biogen in 2013 Q4 according to their latest regulatory filings, with 121 funds opening new positions, 247 increasing their positions, 264 reducing their positions, and 30 closing their positions.
303% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 30
54% more funds holding in top 10
Funds holding in top 10: 24 → 37 (+13)
18% more call options, than puts
Call options by funds: $913M | Put options by funds: $771M
16% more capital invested
Capital invested by funds: $52.6B → $60.8B (+$8.27B)
13% more funds holding
Funds holding: 656 → 738 (+82)
6% less repeat investments, than reductions
Existing positions increased: 247 | Existing positions reduced: 264
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$213M |
| 2 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$186M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$160M |
| 4 |
Morgan Stanley
New York
|
+$101M |
| 5 |
Barclays
London,
United Kingdom
|
+$90.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$493M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$414M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$153M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$125M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$124M |
BIIB Hedge Fund Activity: Q4 2013 in Review
738 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2013, worth a combined $60.8B — up 16% from $52.6B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new BIIB positions and 30 closed out — a net gain of 91 holders — while 247 added to existing stakes and 264 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $213M. The largest seller was JP Morgan Chase, cutting an estimated $493M.
- 738 institutional investors held Biogen (BIIB) as of Q4 2013, up from 656 in Q3 2013.
- Funds reported $60.8B of Biogen stock for Q4 2013, up 16% quarter-over-quarter.
- 121 funds opened new Biogen positions in Q4 2013 and 30 closed out, a net change of +91 holders.
- The largest Biogen buyer in Q4 2013 was T. Rowe Price Associates, an estimated $213M added.
- The largest Biogen seller in Q4 2013 was JP Morgan Chase, an estimated $493M sold.
Based on aggregated 13F filings for Q4 2013.